Minireview: Regulatory T Cells and Ovarian Cancer

References

• Alvero AB, Montagna MK, Craveiro V, et al. (2012). Distinct subpopulations of epithelial ovarian cancer cells can differentially induce macrophages and T regulatory cells toward a pro-tumor phenotype. Am J Repro Immunol, 67, 256–265.
   PubMed Web of Science ®Google Scholar
• Auersperg N, Wong AS, Choi KC, et al. (2001). Ovarian surface epithelium: Biology, endocrinology, and pathology. Endocr Rev, 22, 255–288.
   PubMed Web of Science ®Google Scholar
• Bast RC, Jr, Hennessy B, Mills GB. (2009). The biology of ovarian cancer: New opportunities for translation. Nat Rev Cancer, 9, 415–428.
   PubMed Web of Science ®Google Scholar
• Bottoni P, Scatena R. (2015). The role of CA 125 as tumor barker: Biochemical and clinical aspects. Adv Exp Med Biol, 867, 229–244.
   PubMed Web of Science ®Google Scholar
• Brtnicky T, Fialova A, Lastovicka J, et al. (2015). Clinical relevance of regulatory T cells monitoring in the peripheral blood of ovarian cancer patients. Hum Immunol, 76, 187–191.
   PubMed Web of Science ®Google Scholar
• Bu M, Shen Y, Seeger WL, et al. (2016). Ovarian carcinoma-infiltrating regulatory T cells were more potent suppressors of CD8 T cell inflammation than their peripheral counterparts, a function dependent on TIM3 expression. Tum Biol: J Int Soc Oncodev Biol Med, 37, 3949–3956.
   Google Scholar
• Buckanovich RJ, Facciabene A, Kim S, et al. (2008). Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy. Nat Med, 14, 28–36.
   PubMed Web of Science ®Google Scholar
• Cannistra SA. (2004). Cancer of the ovary. N Engl J Med, 351, 2519–2529.
   PubMed Web of Science ®Google Scholar
• Charbonneau B, Goode EL, Kalli KR, et al. (2013). The immune system in the pathogenesis of ovarian cancer. Crit Rev Immunol, 33, 137–164.
   PubMed Web of Science ®Google Scholar
• Charbonneau B, Moysich KB, Kalli KR, et al. (2014). Large-scale evaluation of common variation in regulatory T cell-related genes and ovarian cancer outcome. Cancer Immunol Res, 2, 332–340.
   PubMed Web of Science ®Google Scholar
• Chen YL, Chang MC, Chen CA, et al. (2012). Depletion of regulatory T lymphocytes reverses the imbalance between pro- and anti-tumor immunities via enhancing antigen-specific T cell immune responses. PloS One, 7, e47190.
   PubMed Web of Science ®Google Scholar
• Chu CS, Boyer J, Schullery DS, et al. (2012). Phase I/II randomized trial of dendritic cell vaccination with or without cyclophosphamide for consolidation therapy of advanced ovarian cancer in first or second remission. Cancer Immunol, Immunother CII, 61, 629–641.
   PubMed Web of Science ®Google Scholar
• Conejo-Garcia JR, Benencia F, Courreges MC, et al. (2004). Tumor-infiltrating dendritic cell precursors recruited by a beta-defensin contribute to vasculogenesis under the influence of Vegf-A. Nat Med, 10, 950–958.
   PubMed Web of Science ®Google Scholar
• Conrad C, Gilliet M. (2013). Plasmacytoid dendritic cells and regulatory T cells in the tumor microenvironment: A dangerous liaison. Oncoimmunol, 2, e23887.
   PubMed Web of Science ®Google Scholar
• Coukos G, Benencia F, Buckanovich RJ, Conejo-Garcia JR. (2005). The role of dendritic cell precursors in tumour vasculogenesis. Br J Cancer, 92, 1182–1187.
   PubMed Web of Science ®Google Scholar
• Coukos G, Courreges MC, Benencia F. (2003). Intraperitoneal oncolytic and tumor vaccination therapy with replication-competent recombinant virus: The herpes paradigm. Curr Gene Ther, 3, 113–125.
   PubMedGoogle Scholar
• Curiel TJ, Coukos G, Zou L, et al. (2004). Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med, 10, 942–949.
   PubMed Web of Science ®Google Scholar
• de Rezende LC, Silva IV, Rangel LB, Guimaraes MC. (2010). Regulatory T cell as a target for cancer therapy. Arch Immunol Ther Exp, 58, 179–190.
   PubMed Web of Science ®Google Scholar
• Dijkgraaf EM, Santegoets SJ, Reyners AK, et al. (2015). A phase 1/2 study combining gemcitabine, Pegintron and p53 SLP vaccine in patients with platinum-resistant ovarian cancer. Oncotarget, 6, 32228–32243.
   PubMed Web of Science ®Google Scholar
• Duraiswamy J, Freeman GJ, Coukos G. (2013a). Therapeutic PD-1 pathway blockade augments with other modalities of immunotherapy T-cell function to prevent immune decline in ovarian cancer. Cancer Res, 73, 6900–6912.
   PubMed Web of Science ®Google Scholar
• Duraiswamy J, Kaluza KM, Freeman GJ, Coukos G. (2013b). Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors. Cancer Res, 73, 3591–3603.
   PubMed Web of Science ®Google Scholar
• Elgert KD, Alleva DG, Mullins DW. (1998). Tumor-induced immune dysfunction: The macrophage connection. J Leukoc Biol, 64, 275–290.
   PubMed Web of Science ®Google Scholar
• Emerson RO, Sherwood AM, Rieder MJ, et al. (2013). High-throughput sequencing of T-cell receptors reveals a homogeneous repertoire of tumour-infiltrating lymphocytes in ovarian cancer. J Pathol, 231, 433–440.
   PubMed Web of Science ®Google Scholar
• Facciabene A, Peng X, Hagemann IS, et al. (2011). Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T(reg) cells. Nature, 475, 226–230.
   PubMed Web of Science ®Google Scholar
• Fialova A, Partlova S, Sojka L, et al. (2013). Dynamics of T-cell infiltration during the course of ovarian cancer: The gradual shift from a Th17 effector cell response to a predominant infiltration by regulatory T-cells. Int J Cancer, 132, 1070–1079.
   PubMed Web of Science ®Google Scholar
• Fricke I, Gabrilovich DI. (2006). Dendritic cells and tumor microenvironment: A dangerous liaison. Immunol Invest, 35, 459–483.
   PubMed Web of Science ®Google Scholar
• Gabrilovich DI, Chen HL, Girgis KR, et al. (1996). Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med, 2, 1096–1103.
   PubMed Web of Science ®Google Scholar
• Gabrilovich DI, Ishida T, Nadaf S, et al. (1999). Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function. Clin Cancer Res, 5, 2963–2970.
   PubMed Web of Science ®Google Scholar
• Geller MA, Cooley S, Judson PL, et al. (2011). A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer. Cytotherapy, 13, 98–107.
   PubMed Web of Science ®Google Scholar
• Govindaraj C, Scalzo-Inguanti K, Madondo M, et al. (2013). Impaired Th1 immunity in ovarian cancer patients is mediated by TNFR2+ Tregs within the tumor microenvironment. Clin Immunol, 149, 97–110.
   PubMed Web of Science ®Google Scholar
• Guo Z, Cheng D, Xia Z, et al. (2013). Combined TIM-3 blockade and CD137 activation affords the long-term protection in a murine model of ovarian cancer. J Transl Med, 11, 215.
   PubMed Web of Science ®Google Scholar
• Hermans C, Anz D, Engel J, et al. (2014). Analysis of FoxP3+ T-regulatory cells and CD8+ T-cells in ovarian carcinoma: Location and tumor infiltration patterns are key prognostic markers. PloS One, 9, e111757.
   PubMed Web of Science ®Google Scholar
• Huarte E, Cubillos-Ruiz JR, Nesbeth YC, et al. (2008). Depletion of dendritic cells delays ovarian cancer progression by boosting antitumor immunity. Cancer Research, 68, 7684–7691.
   PubMed Web of Science ®Google Scholar
• Jang M, Yew PY, Hasegawa K, et al. (2015). Characterization of T cell repertoire of blood, tumor, and ascites in ovarian cancer patients using next generation sequencing. Oncoimmunol, 4, e1030561.
   PubMedGoogle Scholar
• Kandalaft LE, Chiang CL, Tanyi J, et al. (2013). A Phase I vaccine trial using dendritic cells pulsed with autologous oxidized lysate for recurrent ovarian cancer. J Transl Med, 11, 149.
   PubMed Web of Science ®Google Scholar
• Kim PS, Jochems C, Grenga I, et al. (2014). Pan-Bcl-2 inhibitor, GX15-070 (obatoclax), decreases human T regulatory lymphocytes while preserving effector T lymphocytes: A rationale for its use in combination immunotherapy. J Immunol, 192, 2622–2633.
   PubMed Web of Science ®Google Scholar
• Knutson KL, Maurer MJ, Preston CC, et al. (2015). Regulatory T cells, inherited variation, and clinical outcome in epithelial ovarian cancer. Cancer Immunol Immunother CII, 64, 1495–1504.
   PubMed Web of Science ®Google Scholar
• Kovacsovics-Bankowski M, Chisholm L, Vercellini J, et al. (2014). Detailed characterization of tumor infiltrating lymphocytes in two distinct human solid malignancies show phenotypic similarities. J Immunother Cancer, 2, 38.
   PubMedGoogle Scholar
• Landskron J, Helland O, Torgersen KM, et al. (2015). Activated regulatory and memory T-cells accumulate in malignant ascites from ovarian carcinoma patients. Cancer Immunol Immunother CII, 64, 337–347.
   PubMed Web of Science ®Google Scholar
• Li X, Wan X, Mao Y, et al. (2010). Low molecular weight fraction secreted by SKOV3 cells expands peripheral CD4+CD25+ regulatory T cells and enhances their suppressive capacity. Med Oncol, 27, 600–606.
   PubMed Web of Science ®Google Scholar
• Lu L, Xu X, Zhang B, et al. (2014). Combined PD-1 blockade and GITR triggering induce a potent antitumor immunity in murine cancer models and synergizes with chemotherapeutic drugs. J Transl Med, 12, 36.
   PubMed Web of Science ®Google Scholar
• Luvero D, Milani A, Ledermann JA. (2014). Treatment options in recurrent ovarian cancer: Latest evidence and clinical potential. Ther Adv Med Oncol, 6, 229–239.
   PubMed Web of Science ®Google Scholar
• Motz GT, Santoro SP, Wang LP, et al. (2014). Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors. Nat Med, 20, 607–615.
   PubMed Web of Science ®Google Scholar
• Nash MA, Ferrandina G, Gordinier M, Loercher A, Freedman RS. (1999). The role of cytokines in both the normal and malignant ovary. Endocr Relat Cancer, 6, 93–107.
   PubMed Web of Science ®Google Scholar
• Park A, Govindaraj C, Xiang SD, et al. (2012). Substantially modified ratios of effector to regulatory T cells during chemotherapy in ovarian cancer patients return to pre-treatment levels at completion: Implications for immunotherapy. Cancers, 4, 581–600.
   PubMedGoogle Scholar
• Pedroza-Gonzalez A, Zhou G, Singh SP, et al. (2015). GITR engagement in combination with CTLA-4 blockade completely abrogates immunosuppression mediated by human liver tumor-derived regulatory T cells. Oncoimmunol, 4, e1051297.
   PubMed Web of Science ®Google Scholar
• Preston CC, Maurer MJ, Oberg AL, et al. (2013). The ratios of CD8+ T cells to CD4+CD25+ FOXP3+ and FOXP3- T cells correlate with poor clinical outcome in human serous ovarian cancer. PloS One, 8, e80063.
   PubMed Web of Science ®Google Scholar
• Pruitt SK, Boczkowski D, de Rosa N, et al. (2011). Enhancement of anti-tumor immunity through local modulation of CTLA-4 and GITR by dendritic cells. Eur J Immunol, 41, 3553–3563.
   PubMed Web of Science ®Google Scholar
• Qu P, Boelte KC, Lin PC. (2012). Negative regulation of myeloid-derived suppressor cells in cancer. Immunol Invest, 41, 562–580.
   PubMed Web of Science ®Google Scholar
• Redjimi N, Raffin C, Raimbaud I, et al. (2012). CXCR3+ T regulatory cells selectively accumulate in human ovarian carcinomas to limit type I immunity. Cancer Res, 72, 4351–4360.
   PubMed Web of Science ®Google Scholar
• Santegoets SJ, Dijkgraaf EM, Battaglia A, et al. (2015). Monitoring regulatory T cells in clinical samples: Consensus on an essential marker set and gating strategy for regulatory T cell analysis by flow cytometry. Cancer Immunol, Immunother CII, 64, 1271–1286.
   PubMed Web of Science ®Google Scholar
• Santin AD, Hermonat PL, Ravaggi A, et al. (1999). Secretion of vascular endothelial growth factor in ovarian cancer. Eur J Gynaecological oncol, 20, 177–181.
   PubMed Web of Science ®Google Scholar
• Sato E, Olson SH, Ahn J, et al. (2005). Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci U S A, 102, 18538–18543.
   PubMed Web of Science ®Google Scholar
• Sawan S, Burt DJ, Stern PL, et al. (2011). Circulating regulatory T cells in endometrial cancer: A role for age and menopausal status. Immunol Invest, 40, 62–75.
   PubMed Web of Science ®Google Scholar
• Shen CC, Kang YH, Zhao M, et al. (2014). WNT16B from ovarian fibroblasts induces differentiation of regulatory T cells through beta-catenin signal in dendritic cells. Int J Mol Sci, 15, 12928–12939.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. (2015). Cancer statistics, 2015. CA: A Cancer J Clin, 65, 5–29.
   PubMed Web of Science ®Google Scholar
• Vermeij R, Leffers N, Hoogeboom BN, et al. (2012). Potentiation of a p53-SLP vaccine by cyclophosphamide in ovarian cancer: A single-arm phase II study. Int J Cancer, 131, E670–680.
   PubMed Web of Science ®Google Scholar
• Wertel I, Surowka J, Polak G, et al. (2015). Macrophage-derived chemokine CCL22 and regulatory T cells in ovarian cancer patients. Tumour Biol: J Int Soc Oncodev Biol Med, 36, 4811–4817.
   Web of Science ®Google Scholar
• Winkler I, Wilczynska B, Bojarska-Junak A, et al. (2015). Regulatory T lymphocytes and transforming growth factor beta in epithelial ovarian tumors-prognostic significance. J Ovarian Res, 8, 39.
   PubMed Web of Science ®Google Scholar
• Yan J, Zhang Y, Zhang JP, et al. (2013). Tim-3 expression defines regulatory T cells in human tumors. PloS One, 8, e58006.
   PubMed Web of Science ®Google Scholar
• Zhang L, Conejo-Garcia JR, Katsaros D, et al. (2003). Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Eng J Med, 348, 203–213.
   PubMed Web of Science ®Google Scholar